Role of lymphocytes in liver cancer

References

• Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis 2009; 27:80 - 92; http://dx.doi.org/10.1159/000218339; PMID: 19546545
   PubMed Web of Science ®Google Scholar
• Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013; 144:512 - 27; http://dx.doi.org/10.1053/j.gastro.2013.01.002; PMID: 23313965
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365:1118 - 27; http://dx.doi.org/10.1056/NEJMra1001683; PMID: 21992124
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134:1752 - 63; http://dx.doi.org/10.1053/j.gastro.2008.02.090; PMID: 18471552
   PubMed Web of Science ®Google Scholar
• Iavarone M, Cabibbo G, Piscaglia F, Zavaglia C, Grieco A, Villa E, Cammà C, Colombo M, SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011; 54:2055 - 63; http://dx.doi.org/10.1002/hep.24644; PMID: 21898496
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436 - 44; http://dx.doi.org/10.1038/nature07205; PMID: 18650914
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883 - 99; http://dx.doi.org/10.1016/j.cell.2010.01.025; PMID: 20303878
   PubMed Web of Science ®Google Scholar
• Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity 2011; 35:467 - 77; http://dx.doi.org/10.1016/j.immuni.2011.09.006; PMID: 22035839
   PubMed Web of Science ®Google Scholar
• Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2008; 66:1 - 9; http://dx.doi.org/10.1016/j.critrevonc.2007.07.004; PMID: 17913510
   PubMed Web of Science ®Google Scholar
• Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010; 29:1093 - 102; http://dx.doi.org/10.1038/onc.2009.416; PMID: 19946335
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557 - 76; http://dx.doi.org/10.1053/j.gastro.2007.04.061; PMID: 17570226
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol 2010; 52:370 - 9; http://dx.doi.org/10.1016/j.jhep.2009.07.013; PMID: 19720422
   PubMed Web of Science ®Google Scholar
• Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128:2436 - 43; http://dx.doi.org/10.1002/ijc.25797; PMID: 21128245
   PubMed Web of Science ®Google Scholar
• White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10:1342 - 59, e2; http://dx.doi.org/10.1016/j.cgh.2012.10.001; PMID: 23041539
   PubMed Web of Science ®Google Scholar
• Torres DM, Harrison SA. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012; 32:30 - 8; http://dx.doi.org/10.1055/s-0032-1306424; PMID: 22418886
   PubMed Web of Science ®Google Scholar
• Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; In press PMID: 23389810
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584 - 93; http://dx.doi.org/10.1001/jama.2012.144878; PMID: 23268517
   PubMed Web of Science ®Google Scholar
• Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010; 52:921 - 9; http://dx.doi.org/10.1016/j.jhep.2009.12.034; PMID: 20385424
   PubMed Web of Science ®Google Scholar
• Vucur M, Roderburg C, Bettermann K, Tacke F, Heikenwalder M, Trautwein C, Luedde T. Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget 2010; 1:373 - 8; PMID: 21307402
   PubMedGoogle Scholar
• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461 - 6; http://dx.doi.org/10.1038/nature02924; PMID: 15329734
   PubMed Web of Science ®Google Scholar
• Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119 - 32; http://dx.doi.org/10.1016/j.ccr.2006.12.016; PMID: 17292824
   PubMed Web of Science ®Google Scholar
• Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO, Bremer J, Iezzi G, Graf R, Clavien PA, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16:295 - 308; http://dx.doi.org/10.1016/j.ccr.2009.08.021; PMID: 19800575
   PubMed Web of Science ®Google Scholar
• Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007; 13:1211 - 8; http://dx.doi.org/10.1038/nm1649; PMID: 17906636
   PubMed Web of Science ®Google Scholar
• Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4:641 - 8; http://dx.doi.org/10.1038/nri1415; PMID: 15286730
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431 - 6; http://dx.doi.org/10.1038/nature04870; PMID: 16724054
   PubMed Web of Science ®Google Scholar
• Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012; 21:504 - 16; http://dx.doi.org/10.1016/j.ccr.2012.02.007; PMID: 22516259
   PubMed Web of Science ®Google Scholar
• Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G, Zimmermann HW, Vucur M, Huss S, Gassler N, et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 2012; 61:1733 - 43; http://dx.doi.org/10.1136/gutjnl-2011-301116; PMID: 22267597
   PubMed Web of Science ®Google Scholar
• Zhao F, Korangy F, Greten TF. Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma. Dig Dis 2012; 30:477 - 82; http://dx.doi.org/10.1159/000341695; PMID: 23108303
   PubMed Web of Science ®Google Scholar
• Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, et al. Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma. Gut 2012; 61:427 - 38; http://dx.doi.org/10.1136/gutjnl-2011-300509; PMID: 21930732
   PubMed Web of Science ®Google Scholar
• Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011; 8:108 - 18; http://dx.doi.org/10.1038/nrgastro.2010.213; PMID: 21293511
   PubMed Web of Science ®Google Scholar
• Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479:547 - 51; http://dx.doi.org/10.1038/nature10599; PMID: 22080947
   PubMed Web of Science ®Google Scholar
• Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007; 117:1137 - 46; http://dx.doi.org/10.1172/JCI31405; PMID: 17476343
   PubMed Web of Science ®Google Scholar
• Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361 - 5; http://dx.doi.org/10.1038/nature11824; PMID: 23376950
   PubMed Web of Science ®Google Scholar
• Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what’s in a name?. Nat Rev Immunol 2004; 4:231 - 7; http://dx.doi.org/10.1038/nri1309; PMID: 15039760
   PubMed Web of Science ®Google Scholar
• Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011; 10:509 - 36; http://dx.doi.org/10.2174/187152811798104890; PMID: 22150762
   PubMedGoogle Scholar
• Wehr A, Baeck C, Heymann F, Niemietz PM, Hammerich L, Martin C, Zimmermann HW, Pack O, Gassler N, Hittatiya K, et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. J Immunol 2013; 190:5226 - 36; http://dx.doi.org/10.4049/jimmunol.1202909; PMID: 23596313
   PubMed Web of Science ®Google Scholar
• Takeda K, Seki S, Ogasawara K, Anzai R, Hashimoto W, Sugiura K, Takahashi M, Satoh M, Kumagai K. Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 1996; 156:3366 - 73; PMID: 8617962
   PubMed Web of Science ®Google Scholar
• Seki S, Hashimoto W, Ogasawara K, Satoh M, Watanabe H, Habu Y, Hiraide H, Takeda K. Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology 1997; 92:561 - 6; http://dx.doi.org/10.1046/j.1365-2567.1997.00383.x; PMID: 9497499
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 2001; 166:6578 - 84; PMID: 11359810
   PubMed Web of Science ®Google Scholar
• Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002; 196:119 - 27; http://dx.doi.org/10.1084/jem.20020092; PMID: 12093876
   PubMed Web of Science ®Google Scholar
• Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, Balk SP, Exley MA. Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167:4046 - 50; PMID: 11564825
   PubMed Web of Science ®Google Scholar
• Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, Yamagoe S, Colnot S, Viguier M, Perret C, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012; 122:586 - 99; http://dx.doi.org/10.1172/JCI43937; PMID: 22251704
   PubMed Web of Science ®Google Scholar
• Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology 2013; 57:1654 - 62; http://dx.doi.org/10.1002/hep.26115; PMID: 23111952
   PubMed Web of Science ®Google Scholar
• Subleski JJ, Wiltrout RH, Weiss JM. Application of tissue-specific NK and NKT cell activity for tumor immunotherapy. J Autoimmun 2009; 33:275 - 81; http://dx.doi.org/10.1016/j.jaut.2009.07.010; PMID: 19682859
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, Zhang H, Yang Y, Wu H, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129:428 - 37; http://dx.doi.org/10.1016/j.clim.2008.08.012; PMID: 18824414
   PubMed Web of Science ®Google Scholar
• Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012; 56:769 - 75; http://dx.doi.org/10.1002/hep.25670; PMID: 22378017
   PubMed Web of Science ®Google Scholar
• Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, Kuppen PJ. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24:603 - 9; http://dx.doi.org/10.1016/j.it.2003.09.007; PMID: 14596885
   PubMed Web of Science ®Google Scholar
• Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology 2008; 48:963 - 77; http://dx.doi.org/10.1002/hep.22413; PMID: 18726940
   PubMed Web of Science ®Google Scholar
• Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 2011; 32:1434 - 40; http://dx.doi.org/10.1093/carcin/bgr133; PMID: 21771728
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21:137 - 48; http://dx.doi.org/10.1016/j.immuni.2004.07.017; PMID: 15308095
   PubMed Web of Science ®Google Scholar
• Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?. Hepatology 1999; 30:413 - 21; http://dx.doi.org/10.1002/hep.510300237; PMID: 10421649
   PubMed Web of Science ®Google Scholar
• Nagao M, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Ko S, Tatekawa Y, Ikeda N, Kanokogi H, Urizono Y, et al. The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology 2000; 32:491 - 500; http://dx.doi.org/10.1053/jhep.2000.16470; PMID: 10960440
   PubMed Web of Science ®Google Scholar
• Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012; 72:887 - 96; http://dx.doi.org/10.1158/0008-5472.CAN-11-2637; PMID: 22205715
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480 - 9; http://dx.doi.org/10.1038/nature10673; PMID: 22193102
   PubMed Web of Science ®Google Scholar
• Maki A, Matsuda M, Asakawa M, Kono H, Fujii H, Matsumoto Y. Decreased expression of CD28 coincides with the down-modulation of CD3zeta and augmentation of caspase-3 activity in T cells from hepatocellular carcinoma-bearing patients and hepatitis C virus-infected patients. J Gastroenterol Hepatol 2004; 19:1348 - 56; http://dx.doi.org/10.1111/j.1440-1746.2004.03455.x; PMID: 15610307
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Farber A, Cantz T, Petrykowska S, Wedemeyer H, Horning M, Lehner F, Manns MP, Korangy F, Greten TF. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. World J Gastroenterol 2006; 12:3275 - 82; PMID: 16718852
   PubMed Web of Science ®Google Scholar
• Behboudi S, Alisa A, Boswell S, Anastassiou J, Pathan AA, Williams R. Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease. Br J Cancer 2010; 102:748 - 53; http://dx.doi.org/10.1038/sj.bjc.6605526; PMID: 20087354
   PubMed Web of Science ®Google Scholar
• Witkowski M, Spangenberg HC, Neumann-Haefelin C, Büttner N, Breous E, Kersting N, Drognitz O, Hopt UT, Blum HE, Semmo N, et al. Lack of ex vivo peripheral and intrahepatic α-fetoprotein-specific CD4+ responses in hepatocellular carcinoma. Int J Cancer 2011; 129:2171 - 82; http://dx.doi.org/10.1002/ijc.25866; PMID: 21170957
   PubMed Web of Science ®Google Scholar
• Wu K, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 2009; 69:8067 - 75; http://dx.doi.org/10.1158/0008-5472.CAN-09-0901; PMID: 19826049
   PubMed Web of Science ®Google Scholar
• Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol 2011; 11:879 - 89; http://dx.doi.org/10.1016/j.intimp.2010.12.024; PMID: 21241810
   PubMed Web of Science ®Google Scholar
• Tacke F, Yoneyama H. From NAFLD to NASH to fibrosis to HCC: role of dendritic cell populations in the liver. Hepatology 2013; 58:494 - 6; http://dx.doi.org/10.1002/hep.26405; PMID: 23519833
   PubMed Web of Science ®Google Scholar
• Flecken T, Schmidt N, Spangenberg HC, Thimme R. [Hepatocellular carcinoma - from immunobiology to immunotherapy]. Z Gastroenterol 2012; 50:47 - 56; PMID: 22222798
   PubMed Web of Science ®Google Scholar
• Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65:2457 - 64; http://dx.doi.org/10.1158/0008-5472.CAN-04-3232; PMID: 15781662
   PubMed Web of Science ®Google Scholar
• Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, Zheng SS. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One 2011; 6:e24671; http://dx.doi.org/10.1371/journal.pone.0024671; PMID: 21935436
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z, Shi M, Zhao P, Fu B, Zhang Z, Yang H, Zhang H, Zhou C, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132:2328 - 39; http://dx.doi.org/10.1053/j.gastro.2007.03.102; PMID: 17570208
   PubMed Web of Science ®Google Scholar
• Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, Kanto T, Kasugai T, Katayama K, Kato M, et al. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 2008; 99:1643 - 9; http://dx.doi.org/10.1111/j.1349-7006.2008.00859.x; PMID: 18754878
   PubMed Web of Science ®Google Scholar
• Kumar V, Kato N, Urabe Y, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Omata M, Nakagawa H, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43:455 - 8; http://dx.doi.org/10.1038/ng.809; PMID: 21499248
   PubMed Web of Science ®Google Scholar
• Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. Dig Dis 2012; 30:483 - 91; http://dx.doi.org/10.1159/000341697; PMID: 23108304
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006; 12:2817 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-05-2856; PMID: 16675576
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003; 9:5902 - 8; PMID: 14676113
   PubMed Web of Science ®Google Scholar
• Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009; 49:124 - 32; http://dx.doi.org/10.1002/hep.22626; PMID: 18980227
   PubMed Web of Science ®Google Scholar
• Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28:496 - 504; http://dx.doi.org/10.1097/01.cji.0000171291.72039.e2; PMID: 16113606
   PubMed Web of Science ®Google Scholar
• Greten TF, Ormandy LA, Fikuart A, Höchst B, Henschen S, Hörning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010; 33:211 - 8; http://dx.doi.org/10.1097/CJI.0b013e3181bb499f; PMID: 20139774
   PubMed Web of Science ®Google Scholar
• Lygidakis NJ, Kosmidis P, Ziras N, Parissis J, Kyparidou E. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 1995; 15:467 - 72; http://dx.doi.org/10.1089/jir.1995.15.467; PMID: 7544232
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378 - 90; http://dx.doi.org/10.1056/NEJMoa0708857; PMID: 18650514
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-1377; PMID: 17178882
   PubMed Web of Science ®Google Scholar
• Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, et al. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. Hepatology 2013; 57:2358 - 68; http://dx.doi.org/10.1002/hep.26328; PMID: 23424039
   PubMed Web of Science ®Google Scholar